Genelux Valuation Multiples

Genelux Overview

About Genelux

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Founded

2001

HQ

Employees

24

Website

genelux.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

Net Income: ($33M)

EV

$102M

Valuation Multiples

Multiples.vc

Start free trial

Genelux Financials

Genelux reported last 12-month revenue of —.

In the same LTM period, Genelux generated — in gross profit and had net loss of ($33M).

Genelux P&L

In the most recent fiscal year, Genelux reported revenue of $8K and EBITDA of ($25M).

Genelux expects next 12-month revenue of XXX and NTM EBITDA of XXX

Genelux Stock Performance

Genelux has current market cap of $120M, and enterprise value of $102M.

Genelux's stock price is $2.69.

Genelux Valuation Multiples

Genelux trades at 12739.0x EV/Revenue multiple, and (4.1x) EV/EBITDA.

Genelux Financial Valuation Multiples

As of March 18, 2026, Genelux has market cap of $120M and EV of $102M.

Equity research analysts estimate Genelux's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genelux has a P/E ratio of (3.6x).

Genelux Margins & Growth Rates

Genelux's revenue in the last fiscal year declined by (100%).

Genelux's revenue per employee in the last FY averaged $0.0M.

Genelux Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Genelux M&A Activity

Genelux acquired XXX companies to date.

Last acquisition by Genelux was on XXXXXXXX, XXXXX. Genelux acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Genelux Investment Activity

Genelux invested in XXX companies to date.

Genelux made its latest investment on XXXXXXXX, XXXXX. Genelux invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).